PCM
AKRO

Peregrine Capital Management’s Akero Therapeutics AKRO Stock Holding History

Peregrine Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-95,447
Closed -$4.83M – 319
2023
Q3 		$4.83M Buy
+95,447
New +$4.44M 0.14% 233

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Peregrine Capital Management's AKRO Position: Q4 2023 in Review

Peregrine Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 95,447 shares — an estimated $4.83M sold.

Peregrine Capital Management first reported a position in AKRO in Q3 2023 and held it in 1 quarter. The position peaked at $4.83M in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Peregrine Capital Management reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Peregrine Capital Management sold 95,447 Akero Therapeutics shares in Q4 2023, an estimated $4.83M.
  • Peregrine Capital Management first reported a position in Akero Therapeutics in Q3 2023 and held it in 1 quarter.
  • Peregrine Capital Management's Akero Therapeutics position peaked at $4.83M in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Peregrine Capital Management's 13F filing for Q4 2023, filed 26 Jan 2024.